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Summary
  In women with early stage breast cancer brachytherapy (BR) boost allows increase 
of the dose administered to the tumour bed, following whole-breast irradiation. In 
the present paper high-dose-rate and low-dose-rate brachytherapy results are pre-
sented, in comparison to external electron beam radiotherapy. Results of Phase 
II and III trials show that both techniques give comparable results regarding ef-
fi cacy. In most patients satisfying cosmetic results can also be obtained, with ac-
ceptable local recurrence rate not exceeding 10%.
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The history of brachytherapy (BR) in Europe be-
gan in 1901, when the Head of the Dermatology 
Ward in St. Luis Hospital in Paris, Henry 
Alexander Danlos, used radium for the treat-
ment of lupus erythematosus type skin malforma-
tion. He placed several milligrams of this radio-
active element (borrowed from Marie and Pierre 
Curie) in a rubber tube directly on the skin of the 
patient [1]. In the years 1924–1929 the British 
surgeon Geoffrey Keynes treated 90 breast can-
cer patients using radium irradiation exclusive-
ly [2]. Nowadays, radiotherapy alone is used in 
patients with locally advanced breast cancer who 
do not accept surgical treatment or if contraindi-
cations to surgery are present. In those cases the 
whole breast is irradiated (50Gy external beam 
radiotherapy). BR is one of the methods allow-
ing an increase of the dose delivered to the tu-
mour [3,4]. BR alone is the treatment of choice 
in patients with locally recurrent breast cancer 
after breast conserving treatment (including ra-
diotherapy), who refused mastectomy [5–7].
Breast conserving treatment is the treatment of 
choice in early cancer. Despite years of observa-
tion it is still regarded as controversial – not in 
regard to the very idea; the controversy pertains 
rather to the way it is being performed by radio-
therapists and surgeons. There are no uniform 
indications as far as the optimal surgery range 
is concerned (lumpectomy alone, lumpecto-
my with the macroscopic margin of 1cm, exci-
sion of the breast tissue block of a segment or 
a quadrant).
Breast irradiation is an essential element of the 
conservative approach. Local recurrence risk 
after surgery alone reaches 35%, compared to 
10% in patients undergoing adjuvant radiother-
apy [8]. First, the whole breast is irradiated us-
ing external beam technique, usually with a dose 
of 50Gy. Subsequently it is necessary to increase 
the dose delivered to the tumour bed using a so-
called “boost”. There is no generally accepted 
term for the boost in Polish radiological vocab-
ulary. The authors of this article decided to use 
the term “dopromienianie”, proposed by Fijutha 
and Nagadowska in 1996 [9].
Primary boost dose methods include teleradio-
therapy (TRT) with external photon or electron 
(usually) beam and high dose rate (HDR) or low 
dose rate (LDR) brachytherapy [10]. The main 
advantage of brachytherapy results from the pos-
sibility of delivering a high dose of radiation to 
a limited volume of tissue in a short time peri-
od. However, one must remember that if the im-
plants are misplaced the high dose irradiation 
area may exceed the tumour bed. Also the radi-
obiological effects of signifi cantly shorter irradi-
ation time are not well known (current models 
of equivalent doses are not applicable to inter-
stitial brachytherapy setting).
BRLDR VERSUS TRT
The only study comparing effi cacy of BRLDR to 
TRT of which results are available in the litera-
ture was conducted in the Curie Institute in Paris. 
Fourquet et al. studied a group of 255 breast can-
cer patients in clinical stages T2–T3, treated with 
irradiation alone. They showed that during the 
5-year follow-up period the recurrence rate af-
ter the electron beam boost was 30% versus 16% 
(p=0.03) in patients receiving the boost from an 
interstitial iridium 192 implant [3].
In Tables 1 and 2 the comparison of the effi cacy 
results of these boost techniques is presented.
The dose of 0.40–0.60Gy /hour was used in all 
cases where BRLDR was applied.
The two methods show similar and comparable 
effi cacy rates. However, it must be noted that the 
analysis was conducted retrospectively. Also, in 
some series in which interstitial boost was used, 
the mean age of patients was signifi cantly lower 
than in the external beam group [11,13,15].
BRHDR VERSUS TRT
In two studies the effi cacy of BRHDR and TRT as 
a boost in non-advanced breast cancer patients 
with breast conserving treatment was compared. 
First, whole breast irradiation was performed us-
ing an external photon beam (50Gy in classical 
fractionation). Subsequently Hammer et al. de-
livered a boost to the tumour bed using either 
an electron beam (TRT-11Gy in 5 fractions) or 
BRHDR (single 10Gy boost). Local recurrence 
rates were 8.2% and 4.3% (p<0.04), respectively. 
Excellent or good cosmetic results were achieved 
in 70% and 88%, respectively (p<0.0001) [19]. 
Polgar et al., in a randomized clinical Phase III 
trial, after the fi rst stage of the study randomized 
the patients into 2 groups. In the fi rst group the 
patients received external electron beam thera-
py of 16Gy in 8 fractions. In the second group 
the same total dose was delivered in the form of 
BRHDR. Local recurrence rates were 6% and 
8.5%, respectively. Excellent or good cosmetic 
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results were achieved in 83% and 88%, respec-
tively [20]. The differences between rates in 
the two groups were not statistically signifi cant. 
Kulik from the Oncology Centre in Warsaw pre-
sented the results of a high dose rate interstitial 
boost study in 93 patients undergoing conserva-
tive treatment. During the 3-year follow-up one 
case of local recurrence was observed; excellent 
or good cosmetic results were achieved in 85% 
of patients. In a ProbRough rule induction analy-
sis including all clinical and therapeutic variables 
it was shown that patients with a mammography 
Author and publication date Number of cases
Percentage of recurrence (%)
p
TRT BRLDR
De la Rochefordiere et al. 1992 [11] 337  7  8 NS
Mansfi eld et al. 1995 [12] 1070  18  12 0.05
Touboul et al. 1995 [13] 329  8  5.5 NS
Perez et al. 1996 [14] 619  6  7 NS
Wazer et al. 1997 [15] 214  3  4 NS
Vicini et al. 1997 [16] 385  4  4 NS
Collette et al. 2000 [17] 5312  4.5  2.5 0.09
Berberich et al. 2002 [18] 229  1.5  5.0 NS
Table 1. Comparison of eff ectiveness of TRT (electrons) and BRLDR irradiation.
NS – not signifi cant.
Author and publication date
TRT BRLDR
p
DCD (Gy) EKZD (%) DCD (Gy) EKZD (%)
De la Rochefordiere et al. [11] 16 97 20 95 NS
Mansfi eld et al. [12] 20 95 20 91 NS
Touboul et al. [13] 15 83 20 62 0.001
Perez et al. [14] 10–20 81 10–20 75 NS
Wazer et al. [15] 20 68 20 90 0.001
Vicini et al. [16] 15 90 15 90 NS
Table 2. Cosmetic eff ect depending on irradiation method.
DCD – total dose from irradiation.
Author and publication year Number of cases DCD (Gy)
Percentage of local 
recurrence
EKZD (%)
Hammer 1994 [19] 208 10 4.3 88
Perera 1995 [22] 39 37.2 2.6 95
Guix 2002 [23] 41 30 7.0 79
Polgar 2002 [20] 56 16 8.5 88
Keisch 2003 [24] 43 34 0.0 88
Kulik 2004 [21] 93 10 1.1 85
Table 3. BRHDR method irradiation results.
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diameter of tumour not exceeding 11mm have 
the best chance of excellent or good cosmetic 
results [21].
The results of BRHDR boost therapy are shown 
in Table 3. In all series shown, the dose rate was 
above 12Gy/hour.
Reaching an unequivocal opinion on which of the 
two boost techniques, TRT or BRHDR, is more ef-
fi cient is not an easy task. Results of the above-cit-
ed studies are inconsistent. Hammer et al. showed 
signifi cantly lower local recurrence rates with sig-
nifi cantly higher rate of excellent and good cos-
metic results for the interstitial boost, while the 
group from the National Oncology Institute in 
Budapest did not confi rm these results in the set-
tings of a randomized study [19,20]. Irrespective 
of the dose rate (HDR or LDR) better cosmetic 
results by BR boost can be explained by the lower 
dose delivered to the skin. This results from the 
fact that the distance between the most “superfi -
cial” interstitial guide needle and the skin should 
reach 5mm. Thus the danger of teleangiectasias 
and fi brosis, which signifi cantly infl uence cosmet-
ic outcomes, is reduced. Due to the beam geom-
etry this cannot be achieved using electron beam 
teleradiotherapy [25].
Questions and doubts:
–  How to precisely defi ne the additionally irra-
diated area (CTV – clinical target volume), if 
there is no PTV (planning target volume) in 
interstitial brachytherapy [26]?
–  What is the optimal safety margin for the tar-
get including the tumour bed – 10, 15 or 20 
mm [10]?
–  How to determine this margin in clinical prac-
tice? The most commonly used methods (leav-
ing metal markers in the wall of the lumpec-
tomy site or using ultrasonography) have an 
error margin of 30–50% [27–30].
–  Are the methods of intraoperative brachyther-
apy applicator placement or intraoperative ex-
ternal beam irradiation therapy better, as far as 
the error margin in CTV determination is con-
cerned [8,22]?
–  Are the cosmetic effects in patients treated with 
intraoperative and postoperative brachythera-
py comparable [31]?
–  What irradiation methods are optimal for spe-
cifi c patient groups?
It seems that those questions could be answered 
by the results of Phase III study (studies?) con-
ducted in comparable patients groups, with uni-
form inclusion, treatment indications and evalu-
ation criteria. It would enable boost procedures 
to be standardized in breast cancer patients un-
dergoing conservative treatment.
CONCLUSIONS
A boost delivered to the tumour bed in non-ad-
vanced breast cancer patients undergoing con-
servative treatment improves the local control 
results. The two currently used techniques of 
local dose increase – with either external elec-
tron beam therapy or interstitial high dose or 
low dose rate brachytherapy – give comparable 
results. In most patients a satisfying cosmetic re-
sult can be achieved, with a local recurrence rate 
not exceeding 10%.
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